Close Menu

NEW YORK (360Dx) – Anticoagulation monitoring technology firm CoaguSense said this week that the US Food and Drug Administration has cleared the company's second-generation prothrombin time/international normalized ratio monitoring system for patients on warfarin (Coumadin).

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.